Acromegaly and Oxidative Stress: Impact on Endothelial Dysfunction and Atherosclerosis

Key words

acromegaly - antioxidative capacity - cardiovascular diseases - endothelial dysfunction - nitric oxide - oxidative stress

• References

• 1 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119: 3189-3202
• 2 Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM. Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 2009; 94: 1111-1117
• 3 Lombardi G, Di Somma C, Grasso LF, Savanelli MC, Colao A, Pivonello R. The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest 2012; 35: 1021-1029
• 4 Muller G, Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid Redox Signal 2009; 11: 1711-1731
• 5 Boero L, Cuniberti L, Magnani N, Manavela M, Yapur V, Bustos M, Gomez Rosso L, Merono T, Marziali L, Viale L, Evelson P, Negri G, Brites F. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf) 2010; 72: 654-660
• 6 Yarman S, Ozden TA, Gokkusu C. The evaluation of lipid peroxidation and acute effect of octreotide on lipid peroxidation in patients with active acromegaly. Clin Chim Acta 2003; 336: 45-48
• 7 Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN. Oxidative Stress and Reduced Antioxidative Status, along with Endothelial Dysfunction in Acromegaly. Horm Metab Res 2013; [Epub ahead of print]
• 8 Morawietz H. Endothelial NADPH oxidases: friends or foes?. Basic Res Cardiol 2011; 106: 521-525
• 9 Muller G, Morawietz H. NAD(P)H oxidase and endothelial dysfunction. Horm Metab Res 2009; 41: 152-158
• 10 Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-2183
• 11 Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, Drummond GR. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24-H32
• 12 Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol 2012; 56: 216-231
• 13 Kampfrath T, Maiseyeu A, Ying Z, Shah Z, Deiuliis JA, Xu X, Kherada N, Brook RD, Reddy KM, Padture NP, Parthasarathy S, Chen LC, Moffatt-Bruce S, Sun Q, Morawietz H, Rajagopalan S. Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways. Circ Res 2011; 108: 716-726
• 14 Olivares-Corichi IM, Viquez MJ, Gutierrez-Lopez L, Ceballos-Reyes GM, Garcia-Sanchez JR. Oxidative stress present in the blood from obese patients modifies the structure and function of insulin. Horm Metab Res 2011; 43: 748-753
• 15 Taye A, Saad AH, Kumar AH, Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol 2010; 627: 42-48
• 16 Seiva FR, Berbert CM, Souza GA, Rocha KK, Ebaid GM, Burneiko RC, Novelli EL. Energy expenditure, lipid profile, oxidative stress, and cardiac energy metabolism after growth hormone treatment in obese young rats. Horm Metab Res 2010; 42: 496-501
• 17 Seiva FR, Chuffa LG, Ebaid GM, Silva T, Fernandes AA, Novelli EL. Calorimetry, morphometry, oxidative stress, and cardiac metabolic response to growth hormone treatment in obese and aged rats. Horm Metab Res 2011; 43: 397-403
• 18 Tada Y, Yano S, Yamaguchi T, Okazaki K, Ogawa N, Morita M, Sugimoto T. Advanced Glycation End Products-induced Vascular Calcification is Mediated by Oxidative Stress: Functional Roles of NAD(P)H-oxidase. Horm Metab Res 2013; [Epub ahead of print]
• 19 Jimenez C, Ayala-Ramirez M, Liu J, Nunez R, Gagel RF. Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. Horm Metab Res 2011; 43: 55-61
• 20 Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003; 107: 926-928